Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Aug 14, 2015; 21(30): 9163-9174
Published online Aug 14, 2015. doi: 10.3748/wjg.v21.i30.9163
Figure 2
Figure 2 SVRw12 intention-to-treatment and modified-intention-to-treatment. SVRw12 rates in ITT (n = 1057) (A), and mITT (n = 952) (B) groups. BOC: Boceprevir; TVR: Telaprevir; ITT: Intention-to-treatment; mITT: Modified intention-to-treatment; TN: Treatment-naïve patients; R: Relapsers; PR: Partial responder; NR: Null responder.

  • Citation: Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174
  • URL: https://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v21.i30.9163